Carboplatin-induced hematuria in a patient with stage I seminoma: a case report.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL
Patricia Capdevila, Cristobal Carrasco, Jorge Aparicio
{"title":"Carboplatin-induced hematuria in a patient with stage I seminoma: a case report.","authors":"Patricia Capdevila, Cristobal Carrasco, Jorge Aparicio","doi":"10.1186/s13256-024-04862-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Platinum-based antineoplastic drugs are widely used in the treatment of solid tumors. Carboplatin is a safe and efficacious adjuvant treatment for stage I seminoma following a risk-adapted treatment strategy. It consists in the administration of one or two courses for patients with one or both of rete testis involvement or tumor size more than 4 cm. Carboplatin is used with the purpose of minimizing nephrotoxicity and ototoxicity caused by cisplatin while achieving excellent results. We present a case of carboplatin-induced hematuria that led to an acute kidney injury as a rare complication.</p><p><strong>Case presentation: </strong>A 48 year-old Caucasian man with no medical history and no history of renal disease presented with a painless testicular mass. He underwent an orchiectomy for stage I testicular seminoma and received one course of adjuvant carboplatin (area under the curve of 7); 2 days later, he developed frank hematuria associated with back pain. The physical examination revealed mild suprapubic tenderness and Goldflam's sign was positive bilaterally. Blood tests did not reveal anemia, his platelet count was normal, and creatinine levels were in range. Due to persisting hematuria requiring continuous bladder irrigation, he was hospitalized to monitor renal function and was initially managed conservatively with intravenous analgesics and adequate hydration. The following day, he developed an acute kidney injury (serum creatinine 1.90 mg/dL, glomerular filtration rate 41 mL/min/m<sup>2</sup>). Transurethral cystoscopy showed a blood clot on the left urinary meatus, which was irrigated and removed, revealing a clear ureteral jet. With no further measures, creatinine started declining and back pain improved. His acute kidney injury resolved in the following 72 hours. Computed tomography urogram showed a left ureteral ectasia with an enhanced urothelium within the upper and middle ureter, suggesting ureteral obstruction. The patient improved completely and was discharged successfully. On further follow-up 2 months later, a computed tomography urogram showed a complete resolution of obstructive changes.</p><p><strong>Conclusions: </strong>Hematuria and acute kidney injury are rare but clinically relevant adverse events associated with the administration of carboplatin, regardless of the administered and accumulated dose. It is crucial to recognize this event and start adequate hydration promptly to prevent further kidney damage and the need for more aggressive measures, such as ureteral stenting or percutaneous nephrostomy.</p>","PeriodicalId":16236,"journal":{"name":"Journal of Medical Case Reports","volume":"18 1","pages":"546"},"PeriodicalIF":0.9000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11569596/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13256-024-04862-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Platinum-based antineoplastic drugs are widely used in the treatment of solid tumors. Carboplatin is a safe and efficacious adjuvant treatment for stage I seminoma following a risk-adapted treatment strategy. It consists in the administration of one or two courses for patients with one or both of rete testis involvement or tumor size more than 4 cm. Carboplatin is used with the purpose of minimizing nephrotoxicity and ototoxicity caused by cisplatin while achieving excellent results. We present a case of carboplatin-induced hematuria that led to an acute kidney injury as a rare complication.

Case presentation: A 48 year-old Caucasian man with no medical history and no history of renal disease presented with a painless testicular mass. He underwent an orchiectomy for stage I testicular seminoma and received one course of adjuvant carboplatin (area under the curve of 7); 2 days later, he developed frank hematuria associated with back pain. The physical examination revealed mild suprapubic tenderness and Goldflam's sign was positive bilaterally. Blood tests did not reveal anemia, his platelet count was normal, and creatinine levels were in range. Due to persisting hematuria requiring continuous bladder irrigation, he was hospitalized to monitor renal function and was initially managed conservatively with intravenous analgesics and adequate hydration. The following day, he developed an acute kidney injury (serum creatinine 1.90 mg/dL, glomerular filtration rate 41 mL/min/m2). Transurethral cystoscopy showed a blood clot on the left urinary meatus, which was irrigated and removed, revealing a clear ureteral jet. With no further measures, creatinine started declining and back pain improved. His acute kidney injury resolved in the following 72 hours. Computed tomography urogram showed a left ureteral ectasia with an enhanced urothelium within the upper and middle ureter, suggesting ureteral obstruction. The patient improved completely and was discharged successfully. On further follow-up 2 months later, a computed tomography urogram showed a complete resolution of obstructive changes.

Conclusions: Hematuria and acute kidney injury are rare but clinically relevant adverse events associated with the administration of carboplatin, regardless of the administered and accumulated dose. It is crucial to recognize this event and start adequate hydration promptly to prevent further kidney damage and the need for more aggressive measures, such as ureteral stenting or percutaneous nephrostomy.

精原细胞瘤 I 期患者卡铂诱发的血尿:病例报告。
背景:铂类抗肿瘤药物被广泛用于实体瘤的治疗。卡铂是一种安全有效的I期精原细胞瘤辅助治疗药物,采用的是风险适应治疗策略。对于一个或两个睾丸受累或肿瘤大小超过 4 厘米的患者,卡铂可用于一个或两个疗程的治疗。使用卡铂的目的是尽量减少顺铂引起的肾毒性和耳毒性,同时取得良好的治疗效果。我们介绍一例卡铂诱发血尿导致急性肾损伤的罕见并发症:一名 48 岁的白种男子,无病史和肾病史,因无痛性睾丸肿块就诊。他因睾丸精原细胞瘤 I 期而接受了睾丸切除术,并接受了一个疗程的卡铂辅助治疗(曲线下面积为 7);2 天后,他出现了伴有腰痛的血尿。体格检查显示耻骨上有轻度压痛,双侧戈德弗兰氏征阳性。血液检查未发现贫血,血小板计数正常,肌酐水平在正常范围内。由于血尿持续存在,需要持续进行膀胱冲洗,他被送进医院监测肾功能,最初采取保守治疗,静脉注射止痛药并补充足够的水分。第二天,他出现了急性肾损伤(血清肌酐 1.90 mg/dL,肾小球滤过率 41 mL/min/m2)。经尿道膀胱镜检查显示左侧尿道口有血凝块,冲洗并取出血凝块后,发现输尿管喷流通畅。在没有采取进一步措施的情况下,肌酐开始下降,背痛也有所改善。他的急性肾损伤在随后的 72 小时内缓解。计算机断层扫描尿路造影显示左侧输尿管异位,输尿管上部和中部的尿路上皮增强,提示输尿管梗阻。患者病情完全好转,顺利出院。2 个月后再次随访时,计算机断层扫描尿路造影显示梗阻性病变完全消失:血尿和急性肾损伤是与卡铂用药相关的罕见但具有临床意义的不良反应,无论用药剂量和累积剂量如何。识别这种情况并及时补充足够的水分至关重要,以防止进一步的肾损伤,并避免采取更激进的措施,如输尿管支架置入术或经皮肾造瘘术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medical Case Reports
Journal of Medical Case Reports Medicine-Medicine (all)
CiteScore
1.50
自引率
0.00%
发文量
436
期刊介绍: JMCR is an open access, peer-reviewed online journal that will consider any original case report that expands the field of general medical knowledge. Reports should show one of the following: 1. Unreported or unusual side effects or adverse interactions involving medications 2. Unexpected or unusual presentations of a disease 3. New associations or variations in disease processes 4. Presentations, diagnoses and/or management of new and emerging diseases 5. An unexpected association between diseases or symptoms 6. An unexpected event in the course of observing or treating a patient 7. Findings that shed new light on the possible pathogenesis of a disease or an adverse effect
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信